644P Tifcemalimab combined with toripalimab and docetaxel as 2nd line treatment for immunotherapy-treated squamous cell non-small cell lung cancer (Sq-NSCLC) patients: A phase Ib/II study

Authors:
  • DLD. Lv
    D. Lv
  • YZY. Zhang
    Y. Zhang
  • ZHZ. He
    Z. He
  • YYY. Yu
    Y. Yu
  • LWL. Wu
    L. Wu
  • MZM. Zhao
    M. Zhao
  • WZW. Zhang
    W. Zhang
  • MZM. Zhang
    M. Zhang
  • ALA. Liu
    A. Liu
  • JSJ. Shi
    J. Shi
  • YCY. Chen
    Y. Chen
  • CWC. Wang
    C. Wang
Publisher website
Google Scholar
Abstract
No abstract available